logo
  Join        Login             Stock Quote

Celgene (CELG) Forecasts Higher Earnings, Revenue For 2013

 January 07, 2013 12:46 PM
 


(By Balachander) Celgene Corp. (NASDAQ: CELG) forecast a rise in earnings and revenue for the full year 2013, and shares of the biopharmaceutical company advanced in Monday trading.

For the full year 2013, the company expects adjusted earnings per share (EPS) in the range of $5.50 to $5.60, on 11.4 percent increase in net product sales to $6.0 billion.

Wall Street analysts, on average, expect EPS of $5.56 per share on revenue growth of 9.70 percent to $6.05 billion for 2013.

Celgene anticipates Revlimid net sales in the range of $4.1 billion to $4.2 billion, including roughly $90 million of negative foreign exchange impact. Assuming constant foreign exchange, Revlimid growth would be 11 to 14 percent.

The company currently markets Revlimid, and Thalomid for the treatment of various forms of multiple myeloma, and VIDAZA for the treatment of myelodysplastic syndromes.

[Related -Celgene Corporation (NASDAQ:CELG): Why Should You Invest In Celgene In 2014?]

The company expects 2012 adjusted EPS at the higher end of its guidance range at roughly $4.90 and total revenues up 14 percent at $5.5 billion.

Analysts expect EPS of $4.88 on revenue of $5.52 billion.

"The accomplishments of 2012 and our outlook for 2013 have positioned us with significant catalysts as we enter a new growth phase for Celgene in all three therapeutic areas of our business – hematology, oncology and inflammation and immunology," commented CEO Bob Hugin. "The increased visibility we now have to many of those catalysts allows us to reaffirm our 2015 targets and give new targets out to 2017."

[Related -Celgene Corporation (CELG): How Q3 Earnings Will Fare?]

The Summit, New Jersey-based company also expects Revlimid net product sales to surpass $1.0 billion for the fourth quarter of 2012.

Further, Celgene still expects adjusted EPS of $8.00 to $9.00 for 2015 on net product sales of $8.0-$9.0 billion.

The stock, which has been trading in the 52-week range of $58.53 to $83.38, added 1.32 percent to trade at $83.17 on Monday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageShould You Invest In The Hottest New Trend In Finance?

Thanks to major changes in regulation, social media and technology, the business of banking has undergone read on...

article imageStrong Attractor in Action Pulling S&P 500 Down

The attractor is formed by the 200-day moving average and the 50% Fibonacci retracement of the up move from read on...

article imageIs The Weak Housing Market A Warning Sign For The US Economy?

Today’s US economic releases – housing starts and business survey data for the manufacturing sector – read on...

article imageShort-term Pullback or Something Worse?

A few weeks ago when we called for a short-term pullback of 4 to 5%, it was due solely to the short-term read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Trying To Beat The Market Is A Fool's Errand
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.